Van Eck Associates Corp Ultragenyx Pharmaceutical Inc. Transaction History
Van Eck Associates Corp
- $77.4 Billion
- Q1 2025
A detailed history of Van Eck Associates Corp transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Van Eck Associates Corp holds 1,793 shares of RARE stock, worth $49,504. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,793
Previous 1,760
1.88%
Holding current value
$49,504
Previous $74,000
12.16%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding RARE
# of Institutions
335Shares Held
89.4MCall Options Held
1.08MPut Options Held
1.04M-
Vanguard Group Inc Valley Forge, PA10MShares$276 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$155 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA4.16MShares$115 Million0.55% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.22MShares$88.9 Million0.01% of portfolio
-
State Street Corp Boston, MA2.62MShares$72.3 Million0.0% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $1.93B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...